


### Amendments to the claims:

This listing of claims replaces all prior listings of claims:

### **Listing of claims:**


1. (Currently Amended) A compound represented by the following formula (1):



wherein,  $R_{11}$ ,  $R_{21}$ ,  $R_{31}$ , and  $R_{41}$  independently denote hydrogen or methyl;  $R_{22}$ ,  $R_{23}$ ,  $R_{32}$ ,  $R_{33}$ ,  $R_{42}$ , and  $R_{43}$  independently denote a hydrogen, a linear alkyl with one to six carbon atoms, a linear alkyl with one to six carbon atoms to which a non-aromatic cyclic alkyl group or substituted or unsubstituted aromatic ring is bound, a non-aromatic cyclic alkyl, or a non-aromatic cyclic alkyl group to which a non-aromatic cyclic alkyl group or a substituted or unsubstituted aromatic ring is bound; the pairs of  $R_{21}$  and  $R_{22}$ ,  $R_{22}$  and  $R_{23}$ ,  $R_{31}$  and  $R_{32}$ ,  $R_{32}$  and  $R_{33}$ ,  $R_{41}$  and  $R_{42}$ , and  $R_{42}$  and  $R_{43}$  independently denote acyclic structures without binding or cyclic structures by binding through a linear alkylene group with a one- to five-carbon main chain, a linear alkylene group with a one- to five-carbon main chain comprising a branched chain with one to six carbons, or a linear alkylene group with a one- to five-carbon main chain comprising a ring structure of one to six carbons;  $X$  denotes hydrogen, a structure identical to that shown to the left of  $X$ , a substituted or unsubstituted alkyl or aryl group in any structure comprising a sulfur atom capable of binding with the sulfur atom in formula (1) through a disulfide bond, or a sulfur atom binding with the


sulfur atom bonded to the terminus of R<sub>22</sub>, R<sub>23</sub>, R<sub>32</sub>, R<sub>33</sub>, R<sub>42</sub>, or R<sub>43</sub>, and located to the left of X, via an intramolecular disulfide bond].

2. (Original) A histone deacetylase inhibitor that comprises the compound of claim 1 as an active ingredient.
3. (Original) An apoptosis-inducing agent that comprises the compound of claim 1 as an active ingredient.
4. (Original) A differentiation-inducing agent that comprises the compound of claim 1 as an active ingredient.
5. (Original) An angiogenesis inhibitor that comprises the compound of claim 1 as an active ingredient.
6. (Original) An anti-metastatic agent comprising the compound of claim 1 as an active ingredient.
7. (Original) A pharmaceutical agent for treating or preventing a disease caused by histone deacetylase 1 or 4, comprising the compound of claim 1 as an active ingredient.
8. (Original) The pharmaceutical agent of claim 7, wherein the disease caused by histone deacetylase 1 or 4 is cancer, autoimmune disease, skin disease, or infectious disease.
9. (Withdrawn) A method for producing the compound of claim 1, which comprises the steps of:  
reacting a compound represented by formula (2)




(wherein, n is same as that defined in formula (1); Hal denotes a halogen atom selected from a chlorine atom, bromine atom, or iodine atom, or an allyl or alkylsulfonyl group useful for a free group; P<sub>2</sub> denotes a protection group for an amino group);

with a compound represented by formula (3)



(wherein R<sub>11</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub>, R<sub>31</sub>, R<sub>32</sub>, R<sub>33</sub>, R<sub>41</sub>, R<sub>42</sub>, and R<sub>43</sub> are same as defined in formula (1); P<sub>2</sub> denotes a protection group for a carboxyl group);


in the presence of a peptide-bonding agent to obtain a compound represented by formula (4)



(wherein n, R<sub>11</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub>, R<sub>31</sub>, R<sub>32</sub>, R<sub>33</sub>, R<sub>41</sub>, R<sub>42</sub>, R<sub>43</sub>, P<sub>1</sub>, P<sub>2</sub>, and Hal are the same as defined above);


subjecting the compound represented by formula (4) to catalytic hydrogenation, acid treatment, or hydrolysis to remove P<sub>1</sub> and P<sub>2</sub>;

and then subjecting to cyclization in the presence of a peptide-bonding agent to obtain a compound represented by formula (5)



(wherein n, R<sub>11</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub>, R<sub>31</sub>, R<sub>32</sub>, R<sub>33</sub>, R<sub>41</sub>, R<sub>42</sub>, R<sub>43</sub>, P<sub>1</sub>, P<sub>2</sub>, and Hal are the same as defined above);

or reacting a compound represented by formula (6)




(wherein R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub>, R<sub>31</sub>, R<sub>32</sub>, R<sub>33</sub>, R<sub>41</sub>, R<sub>42</sub>, R<sub>43</sub>, and P<sub>1</sub> are the same as defined above);

with a compound represented by formula (7)



(wherein n, R<sub>11</sub>, P<sub>2</sub>, and Hal are the same as defined above);

in the presence of a peptide-bonding agent to obtain a compound represented by formula (8)




(wherein n, R<sub>11</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub>, R<sub>31</sub>, R<sub>32</sub>, R<sub>33</sub>, R<sub>41</sub>, R<sub>42</sub>, R<sub>43</sub>, P<sub>1</sub>, P<sub>2</sub>, and Hal are the same as defined above);

subjecting the compound represented by formula (8) to catalytic hydrogenation, acid treatment, fluoride anion treatment, or hydrolysis to remove P<sub>1</sub> and P<sub>2</sub>;

and then subjecting to cyclization in the presence of a peptide-bonding agent to obtain the compound represented by formula (5); following, for both process, the steps of:

reacting the compound represented by formula (5) with a reagent comprising sulfur atoms to obtain a compound represented by formula (9)



(wherein n, R<sub>11</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub>, R<sub>31</sub>, R<sub>32</sub>, R<sub>33</sub>, R<sub>41</sub>, R<sub>42</sub>, and R<sub>43</sub> are the same as defined above; P<sub>3</sub> denotes a protection group for sulfohydryl group);

and then treating the compound represented by formula (9) with an oxidizing agent as well as ammonia or another amine.